This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

DENVER (KDVR) — An advisory panel discussed a report on psilocybin mushrooms and the possibility of easing restrictions on the drug in Denver on Tuesday at 4 p.m.

The panel gave an overview of the comprehensive report, highlighting the importance of community-based models of healing with psilocybin and the need for data collection and therapeutic access to psilocybin in Denver. 

Suggestions offered by Kevin Matthews, President of Denver Psilocybin Mushroom Policy Review Panel, were to train first responders on psilocybin mushroom use and response to a user in crisis, expand civil liberties for its use, create and distribute educational material and public service announcements about the drug.

In 2020, doctors at Johns Hopkins University looked into the effects the active ingredient can have on people with major depressive disorder. After a clinical trial researchers found:

“Two doses of the psychedelic subsistence psilocybin, given with supportive psychotherapy, produced rapid and large reductions in depressive symptoms, with most participants showing improvement and half of study participants achieving remission through the four-week follow-up.”